vs
Side-by-side financial comparison of Hyperscale Data, Inc. (GPUS) and Intellia Therapeutics, Inc. (NTLA). Click either name above to swap in a different company.
Hyperscale Data, Inc. is the larger business by last-quarter revenue ($26.9M vs $23.0M, roughly 1.2× Intellia Therapeutics, Inc.). Hyperscale Data, Inc. runs the higher net margin — -112.0% vs -416.2%, a 304.2% gap on every dollar of revenue. On growth, Intellia Therapeutics, Inc. posted the faster year-over-year revenue change (78.8% vs 38.4%). Hyperscale Data, Inc. produced more free cash flow last quarter ($-56.2M vs $-69.4M). Over the past eight quarters, Intellia Therapeutics, Inc.'s revenue compounded faster (-10.8% CAGR vs -16.3%).
Hyperscale Data, Inc. provides GPU-accelerated computing infrastructure and cloud solutions tailored for AI development, big data processing, and high-performance computing workloads. It primarily serves AI startups, large technology firms, and cloud service providers across North America and the Asia-Pacific region, delivering scalable, high-efficiency computing resources to support complex data processing needs.
Intellia Therapeutics, Inc. is an American clinical-stage biotechnology company focused on developing novel, potentially curative therapeutics leveraging CRISPR-based technologies. The company's in vivo programs use intravenously administered CRISPR as the therapy, in which the company's proprietary delivery technology enables highly precise editing of disease-causing genes directly within specific target tissues. Intellia's ex vivo programs use CRISPR to create the therapy by using engineere...
GPUS vs NTLA — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $26.9M | $23.0M |
| Net Profit | $-30.1M | $-95.8M |
| Gross Margin | 14.5% | — |
| Operating Margin | -117.8% | -428.9% |
| Net Margin | -112.0% | -416.2% |
| Revenue YoY | 38.4% | 78.8% |
| Net Profit YoY | -6670.3% | 25.7% |
| EPS (diluted) | — | $-0.81 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $26.9M | $23.0M | ||
| Q3 25 | $24.3M | $13.8M | ||
| Q2 25 | $25.9M | $14.2M | ||
| Q1 25 | $25.0M | $16.6M | ||
| Q4 24 | $19.4M | $12.9M | ||
| Q3 24 | $31.1M | $9.1M | ||
| Q2 24 | $17.8M | $7.0M | ||
| Q1 24 | $38.4M | $28.9M |
| Q4 25 | $-30.1M | $-95.8M | ||
| Q3 25 | $-13.0M | $-101.3M | ||
| Q2 25 | $-19.1M | $-101.3M | ||
| Q1 25 | $-4.2M | $-114.3M | ||
| Q4 24 | $-445.0K | $-128.9M | ||
| Q3 24 | $-25.5M | $-135.7M | ||
| Q2 24 | $-33.9M | $-147.0M | ||
| Q1 24 | $3.7M | $-107.4M |
| Q4 25 | 14.5% | — | ||
| Q3 25 | 25.8% | — | ||
| Q2 25 | 23.7% | — | ||
| Q1 25 | 21.1% | — | ||
| Q4 24 | 6.5% | — | ||
| Q3 24 | 27.5% | — | ||
| Q2 24 | -21.3% | — | ||
| Q1 24 | 47.4% | — |
| Q4 25 | -117.8% | -428.9% | ||
| Q3 25 | -57.8% | -808.9% | ||
| Q2 25 | -39.2% | -772.2% | ||
| Q1 25 | -25.5% | -726.6% | ||
| Q4 24 | -46.8% | -1059.9% | ||
| Q3 24 | -79.2% | -1589.0% | ||
| Q2 24 | -151.4% | -1998.6% | ||
| Q1 24 | 9.5% | -394.0% |
| Q4 25 | -112.0% | -416.2% | ||
| Q3 25 | -53.5% | -735.2% | ||
| Q2 25 | -73.7% | -710.8% | ||
| Q1 25 | -16.8% | -687.6% | ||
| Q4 24 | -2.3% | -1001.2% | ||
| Q3 24 | -82.3% | -1489.5% | ||
| Q2 24 | -190.7% | -2112.6% | ||
| Q1 24 | 9.7% | -371.3% |
| Q4 25 | — | $-0.81 | ||
| Q3 25 | $-0.39 | $-0.92 | ||
| Q2 25 | $-2.66 | $-0.98 | ||
| Q1 25 | — | $-1.10 | ||
| Q4 24 | $-8.78 | $-1.27 | ||
| Q3 24 | $-24.82 | $-1.34 | ||
| Q2 24 | $-37.81 | $-1.52 | ||
| Q1 24 | $3.32 | $-1.12 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $13.1M | $449.9M |
| Total DebtLower is stronger | $83.1M | — |
| Stockholders' EquityBook value | $119.8M | $671.4M |
| Total Assets | $313.7M | $842.1M |
| Debt / EquityLower = less leverage | 0.69× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $13.1M | $449.9M | ||
| Q3 25 | $24.8M | $511.0M | ||
| Q2 25 | $5.9M | $459.7M | ||
| Q1 25 | $4.2M | $503.7M | ||
| Q4 24 | $4.5M | $601.5M | ||
| Q3 24 | $7.9M | $658.1M | ||
| Q2 24 | $9.6M | $691.1M | ||
| Q1 24 | $18.9M | $791.3M |
| Q4 25 | $83.1M | — | ||
| Q3 25 | $80.0M | — | ||
| Q2 25 | $88.5M | — | ||
| Q1 25 | $92.8M | — | ||
| Q4 24 | $96.7M | — | ||
| Q3 24 | $104.8M | — | ||
| Q2 24 | $106.8M | — | ||
| Q1 24 | $30.0M | — |
| Q4 25 | $119.8M | $671.4M | ||
| Q3 25 | $55.9M | $748.4M | ||
| Q2 25 | $5.5M | $715.3M | ||
| Q1 25 | $6.3M | $779.9M | ||
| Q4 24 | $8.6M | $872.0M | ||
| Q3 24 | $2.7M | $962.6M | ||
| Q2 24 | $26.7M | $971.1M | ||
| Q1 24 | $59.0M | $1.0B |
| Q4 25 | $313.7M | $842.1M | ||
| Q3 25 | $242.4M | $925.3M | ||
| Q2 25 | $213.5M | $898.9M | ||
| Q1 25 | $218.5M | $986.2M | ||
| Q4 24 | $220.8M | $1.2B | ||
| Q3 24 | $231.5M | $1.2B | ||
| Q2 24 | $270.8M | $1.2B | ||
| Q1 24 | $299.8M | $1.3B |
| Q4 25 | 0.69× | — | ||
| Q3 25 | 1.43× | — | ||
| Q2 25 | 16.06× | — | ||
| Q1 25 | 14.71× | — | ||
| Q4 24 | 11.19× | — | ||
| Q3 24 | 38.41× | — | ||
| Q2 24 | 4.00× | — | ||
| Q1 24 | 0.51× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-37.7M | $-69.3M |
| Free Cash FlowOCF − Capex | $-56.2M | $-69.4M |
| FCF MarginFCF / Revenue | -208.7% | -301.6% |
| Capex IntensityCapex / Revenue | 68.6% | 0.5% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-87.1M | $-395.9M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-37.7M | $-69.3M | ||
| Q3 25 | $-17.8M | $-76.9M | ||
| Q2 25 | $-3.1M | $-99.6M | ||
| Q1 25 | $-4.0M | $-148.9M | ||
| Q4 24 | $-9.2M | $-85.2M | ||
| Q3 24 | $3.7M | $-84.8M | ||
| Q2 24 | $-3.7M | $-58.2M | ||
| Q1 24 | $-10.2M | $-120.7M |
| Q4 25 | $-56.2M | $-69.4M | ||
| Q3 25 | $-20.6M | $-76.9M | ||
| Q2 25 | $-3.5M | $-99.9M | ||
| Q1 25 | $-6.8M | $-149.7M | ||
| Q4 24 | $-9.3M | $-86.2M | ||
| Q3 24 | $2.6M | $-86.1M | ||
| Q2 24 | $-5.9M | $-59.2M | ||
| Q1 24 | $-11.6M | $-123.2M |
| Q4 25 | -208.7% | -301.6% | ||
| Q3 25 | -84.5% | -558.2% | ||
| Q2 25 | -13.5% | -701.0% | ||
| Q1 25 | -27.3% | -900.1% | ||
| Q4 24 | -47.6% | -669.4% | ||
| Q3 24 | 8.4% | -945.2% | ||
| Q2 24 | -33.4% | -850.9% | ||
| Q1 24 | -30.3% | -425.7% |
| Q4 25 | 68.6% | 0.5% | ||
| Q3 25 | 11.5% | 0.2% | ||
| Q2 25 | 1.5% | 1.7% | ||
| Q1 25 | 11.5% | 4.4% | ||
| Q4 24 | 0.3% | 7.6% | ||
| Q3 24 | 3.6% | 14.0% | ||
| Q2 24 | 12.6% | 14.5% | ||
| Q1 24 | 3.7% | 8.7% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | -2.75× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
GPUS
| Transferred Over Time | $10.4M | 39% |
| Revenue From Mined Crypto Assets At Sentinum Owned And Operated Facilities | $5.8M | 21% |
| Hotel And Real Estate Operations | $4.8M | 18% |
| Other | $4.0M | 15% |
| Turn On Green | $2.0M | 7% |
NTLA
| Avencell Therapeutics Inc | $21.0M | 91% |
| Other | $1.0M | 4% |
| Avencell | $1.0M | 4% |
